...acid from the body. The company's management team includes several executives from Relypsa Inc. and Ilypsa Inc.... ...Ltd. acquired Relypsa in 2016, giving it hyperkalemia drug Veltassa patiromer. Amgen Inc. (NASDAQ:AMGN) bought Ilypsa... ...Tricida's largest shareholder, with 37%, while Sibling Capital holds 23% and Longitude Capital owns 10%.
Paul Bonanos
TRC101
Ilypsa Inc.
Relypsa...
...both are hoping Tricida is the next version of Relypsa Inc. (NASDAQ:RLYP) and its predecessor Ilypsa Inc.... ...and CEO Gerrit Klaerner, who co-founded both Relypsa and Ilypsa, and was Relypsa's president and Ilypsa's... ...is Veltassa patiromer, a high-capacity, non-absorbed potassium binder marketed to treat hyperkalemia in CKD patients. Ilypsa...
...in its first fund, which closed at $65 million in the fall of 2002, included Ilypsa Inc.... ...received a return of about 7x when Amgen Inc. bought chronic kidney disease (CKD) company Ilypsa... ...3x. 5AM still owns a minority stake in the CKD company, which spun out of Ilypsa...
...If Relypsa is acquired, it would amount to double-dipping for 5AM. Relypsa spun out of Ilypsa Inc.... ...firm according to an interview with 5AM's Andy Schwab in 2009. Amgen Inc. (NASDAQ:AMGN) acquired Ilypsa...
...Ilypsa Inc. to develop non-absorbed ion binding polymers to help treat renal diseases. Amgen Inc. acquired Ilypsa... ...co-founder of Ilypsa Inc. and of combinatorial chemistry company Symyx Technologies Inc. , which spun out Ilypsa...
...acid from the body. The company's management team includes several executives from Relypsa Inc. and Ilypsa Inc.... ...Ltd. acquired Relypsa in 2016, giving it hyperkalemia drug Veltassa patiromer. Amgen Inc. (NASDAQ:AMGN) bought Ilypsa... ...Tricida's largest shareholder, with 37%, while Sibling Capital holds 23% and Longitude Capital owns 10%.
Paul Bonanos
TRC101
Ilypsa Inc.
Relypsa...
...both are hoping Tricida is the next version of Relypsa Inc. (NASDAQ:RLYP) and its predecessor Ilypsa Inc.... ...and CEO Gerrit Klaerner, who co-founded both Relypsa and Ilypsa, and was Relypsa's president and Ilypsa's... ...is Veltassa patiromer, a high-capacity, non-absorbed potassium binder marketed to treat hyperkalemia in CKD patients. Ilypsa...
...in its first fund, which closed at $65 million in the fall of 2002, included Ilypsa Inc.... ...received a return of about 7x when Amgen Inc. bought chronic kidney disease (CKD) company Ilypsa... ...3x. 5AM still owns a minority stake in the CKD company, which spun out of Ilypsa...
...If Relypsa is acquired, it would amount to double-dipping for 5AM. Relypsa spun out of Ilypsa Inc.... ...firm according to an interview with 5AM's Andy Schwab in 2009. Amgen Inc. (NASDAQ:AMGN) acquired Ilypsa...
...Ilypsa Inc. to develop non-absorbed ion binding polymers to help treat renal diseases. Amgen Inc. acquired Ilypsa... ...co-founder of Ilypsa Inc. and of combinatorial chemistry company Symyx Technologies Inc. , which spun out Ilypsa...